Jump to Navigation
Trends and Sentiments
Comments and Analysis
S&P cuts Atlantic City credit rating
It looks like Tim Tebow is going to make the Eagles
$18 million up for grabs in this week's 'Dota 2...
Exxon Mobil - What To Do After Friday's Sell-Off
Phillips 66 Could Cross $100 Over The Next 2 Years
It's Not Time To Bail On Chevron
Valero Energy Continues To Surprise
Chefs' Warehouse's (CHEF) CEO Chris Pappas on...
Voya Financial Inc. Is A Rare Opportunity In Today's...
Chesapeake's Outlook, Assuming Current Low Oil And...
Emisphere: Crown Jewel In Oral B12
Analyzing Wednesday's Noteworthy Insider Buys And Sells
7 Healthcare Stocks With January Catalysts
Analyzing Friday's Noteworthy Insider Buys And Sells
Novel Cancer Treatment Gains Acceptance
Targeted Chemotherapy: The Perfect Balance Between Safety And Efficacy?
Hyper-Novel Investments For Targeting Cancer
Notable Micro Cap Insider Buys Last Week
Biotechnology And Drug Stocks Up For FDA Approval In August
Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Cancer Treatment Need Is The Mother Of Novel Solutions
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
Interview: Delcath's CEO Provides Details About The Resubmission Of The FDA's New Drug Application For CHEMOSAT
Delcath Systems: A Frustrating Stock With Quite A Bit Of Value Potential
Biotech Weekend Recap: Bears, Bears Everywhere
Delcath Systems Management Discusses Q3 2012 Results - Earnings Call Transcript
Delcath Systems' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Q3 2012 Pharma Company Updates Indicate Upcoming Catalysts
Three Reasons Delcath Systems Appears Undervalued
Is Delcath The Post-Celsion Play On Liver Cancer?
Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay
The Business Of Cancer
Delcath Systems: 'Improving The Bicycle' In Chemotherapy
Delcath Systems: Bullish On Melblez FDA Panel Vote And Subsequent Approval
CDC: 358 People In 26 States Confirmed To Have...
How weak regulation is helping to build corporate...
EUR/GBP: 1.4232 USD/EUR: 1.0950 JPY/USD: 123.9540
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions